了解t细胞对SARS-CoV-2的反应

IF 0.7 4区 医学
Chaimae Kadi, Nouhaila Najimi, Menanne Zakaria, Bakri Youssef, Elmtili Noureddine, Seghrouchni Fouad
{"title":"了解t细胞对SARS-CoV-2的反应","authors":"Chaimae Kadi, Nouhaila Najimi, Menanne Zakaria, Bakri Youssef, Elmtili Noureddine, Seghrouchni Fouad","doi":"10.1177/1721727x231211458","DOIUrl":null,"url":null,"abstract":"Following infection with SARS-CoV-2, cellular components of the adaptive immune system play a crucial role in eliminating the virus. Specifically, virus-specific CD4+ and CD8+ T cells generate effector cytokines and display cytotoxic activity. A number of studies carried out during the COVID-19 pandemic highlighted the importance of CD4+ T cells, CD8+ T cells, and memory cells in this process. T-cell responses emerge early and contribute to protection, but are comparatively impaired in severe cases, often accompanied by intense activation or lymphopenia. Since December 2020, SARS-CoV-2 vaccines have been licensed and administered worldwide. These vaccines induce a targeted T-cell response against SARS-CoV-2. The cellular response after the third dose was strong and superior to that obtained with the second dose. COVID-19 multiple vaccines elicit a robust CD4+ and CD8+ T cell response after the short-term booster. While, the T-cell response induced by COVID-19 vaccines has been shown to decline within 6-12 months of vaccination. In addition, the long-term persistence of cellular immunity may protect against the development of severe disease. In addition, adoptive T-cell therapies have shown considerable potential in the development of COVID-19 traitement. These therapies involve the transfer of T cells with specific antiviral properties into patients to boost their immune response against SARS-CoV-2.","PeriodicalId":11913,"journal":{"name":"European Journal of Inflammation","volume":"12 7","pages":"0"},"PeriodicalIF":0.7000,"publicationDate":"2023-11-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Insights into the T-cell response to SARS-CoV-2\",\"authors\":\"Chaimae Kadi, Nouhaila Najimi, Menanne Zakaria, Bakri Youssef, Elmtili Noureddine, Seghrouchni Fouad\",\"doi\":\"10.1177/1721727x231211458\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Following infection with SARS-CoV-2, cellular components of the adaptive immune system play a crucial role in eliminating the virus. Specifically, virus-specific CD4+ and CD8+ T cells generate effector cytokines and display cytotoxic activity. A number of studies carried out during the COVID-19 pandemic highlighted the importance of CD4+ T cells, CD8+ T cells, and memory cells in this process. T-cell responses emerge early and contribute to protection, but are comparatively impaired in severe cases, often accompanied by intense activation or lymphopenia. Since December 2020, SARS-CoV-2 vaccines have been licensed and administered worldwide. These vaccines induce a targeted T-cell response against SARS-CoV-2. The cellular response after the third dose was strong and superior to that obtained with the second dose. COVID-19 multiple vaccines elicit a robust CD4+ and CD8+ T cell response after the short-term booster. While, the T-cell response induced by COVID-19 vaccines has been shown to decline within 6-12 months of vaccination. In addition, the long-term persistence of cellular immunity may protect against the development of severe disease. In addition, adoptive T-cell therapies have shown considerable potential in the development of COVID-19 traitement. These therapies involve the transfer of T cells with specific antiviral properties into patients to boost their immune response against SARS-CoV-2.\",\"PeriodicalId\":11913,\"journal\":{\"name\":\"European Journal of Inflammation\",\"volume\":\"12 7\",\"pages\":\"0\"},\"PeriodicalIF\":0.7000,\"publicationDate\":\"2023-11-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European Journal of Inflammation\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1177/1721727x231211458\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Inflammation","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/1721727x231211458","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

感染SARS-CoV-2后,适应性免疫系统的细胞成分在消除病毒方面起着至关重要的作用。具体来说,病毒特异性CD4+和CD8+ T细胞产生效应细胞因子并显示细胞毒性活性。在新冠肺炎大流行期间开展的多项研究强调了CD4+ T细胞、CD8+ T细胞和记忆细胞在这一过程中的重要性。t细胞反应早期出现并有助于保护,但在严重的情况下相对受损,通常伴有强烈的激活或淋巴细胞减少。自2020年12月以来,SARS-CoV-2疫苗已在全球范围内获得许可和使用。这些疫苗诱导针对SARS-CoV-2的靶向t细胞反应。第三次剂量后的细胞反应较第二次剂量强且优于第二次剂量。COVID-19多种疫苗在短期增强后可引起强大的CD4+和CD8+ T细胞反应。而COVID-19疫苗诱导的t细胞反应在疫苗接种后6-12个月内下降。此外,细胞免疫的长期持续可以防止严重疾病的发展。此外,过继性t细胞疗法在COVID-19治疗方面显示出相当大的潜力。这些疗法涉及将具有特定抗病毒特性的T细胞转移到患者体内,以增强其对SARS-CoV-2的免疫反应。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Insights into the T-cell response to SARS-CoV-2
Following infection with SARS-CoV-2, cellular components of the adaptive immune system play a crucial role in eliminating the virus. Specifically, virus-specific CD4+ and CD8+ T cells generate effector cytokines and display cytotoxic activity. A number of studies carried out during the COVID-19 pandemic highlighted the importance of CD4+ T cells, CD8+ T cells, and memory cells in this process. T-cell responses emerge early and contribute to protection, but are comparatively impaired in severe cases, often accompanied by intense activation or lymphopenia. Since December 2020, SARS-CoV-2 vaccines have been licensed and administered worldwide. These vaccines induce a targeted T-cell response against SARS-CoV-2. The cellular response after the third dose was strong and superior to that obtained with the second dose. COVID-19 multiple vaccines elicit a robust CD4+ and CD8+ T cell response after the short-term booster. While, the T-cell response induced by COVID-19 vaccines has been shown to decline within 6-12 months of vaccination. In addition, the long-term persistence of cellular immunity may protect against the development of severe disease. In addition, adoptive T-cell therapies have shown considerable potential in the development of COVID-19 traitement. These therapies involve the transfer of T cells with specific antiviral properties into patients to boost their immune response against SARS-CoV-2.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
European Journal of Inflammation
European Journal of Inflammation Medicine-Immunology and Allergy
自引率
0.00%
发文量
54
期刊介绍: European Journal of Inflammation is a multidisciplinary, peer-reviewed, open access journal covering a wide range of topics in inflammation, including immunology, pathology, pharmacology and related general experimental and clinical research.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信